Background: This study aimed to report the 12-month results of drug-eluting stent (DES) for the treatment of significant restenosis of the hemodialysis access.
Materials And Methods: A total of 14 patients (seven men and seven women; median age 70 years; range of 50-83 years) with significant restenosis of hemodialysis accesses were enrolled from January 2017 to December 2018. A total of 10 arteriovenous graft (AVG) and four arteriovenous fistulae were treated with DES. Study outcomes included primary patency of the target lesion and circuit.
Results: Venous anastomosis of the AVG was the most common target lesion for DES insertion (nine hemodialysis accesses). The range of follow-up time was 12-36 months. Primary patency rates of target lesion before DES (patency for last conventional balloon angioplasty [CBA]) versus target lesion after DES at 6 and 12 months were 29% versus 100% and 7% versus 86% (p < 0.001). Primary patency rates of pre-DES circuit (patency for last CBA) versus post-DES circuit at 6 and 12 months were 29% versus 64% and 7% versus 29%, respectively (p = 0.058).
Conclusion: DES might improve the patency rate of target lesion in patients with significant restenosis of the hemodialysis access.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/sdi.12993 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Prospective Randomized Trial Comparing 2 Different Paclitaxel-Coated Balloons in De Novo Coronary Artery Disease.
JACC Asia
January 2025
Division of Cardiology, Department of Internal Medicine, Chungbuk National University Hospital, Chungbuk National University, College of Medicine, Cheongju, South Korea.
Background: The Genoss paclitaxel-coated balloon (PCB) is a novel PCB with shellac and vitamin E as excipients, enhancing drug delivery to the target lesion and minimizing restenosis.
Objectives: This study aimed to compare quantitative coronary angiographic outcomes at 6 months after treatment of de novo coronary artery disease (CAD) with 2 different types of PCBs.
Methods: This prospective, multicenter, noninferiority trial randomized 204 patients with chronic coronary syndrome or stabilized acute coronary syndrome to treatment with the shellac and vitamin E-based PCB or the reference PCB (SeQuent Please NEO) in a 1:1 ratio.
Non-Target Hemangioma Size Reduction After Bleomycin-Lipiodol Embolization of Primary Hepatic Hemangioma.
J Vasc Interv Radiol
January 2025
Inonu University, Faculty of Medicine, Department of Biostatistics and Medical Informatics, Malatya, Türkiye.
Purpose: To evaluate changes in non-target hepatic hemangiomas, which are neither subjected to embolization nor targeted for treatment, following selective bleomycin-lipiodol transarterial chemoembolization (TACE) of a giant hepatic hemangioma.
Materials And Methods: This single-center retrospective study included 24 patients with non-target hepatic hemangiomas distinct from primary giant hemangiomas treated with selective bleomycin-lipiodol TACE between 2009 and 2022. The size and volume of the lesions were assessed using computed tomography scans obtained before treatment, and at 6, 12 and 24 months.
Using cortical organoids to understand the pathogenesis of malformations of cortical development.
Front Neurosci
January 2025
Department of Neurology, Rosamund Stone Zander Translational Neuroscience Center, Boston Children's Hospital, Harvard Medical School, Boston, MA, United States.
Malformations of cortical development encompass a broad range of disorders associated with abnormalities in corticogenesis. Widespread abnormalities in neuronal formation or migration can lead to small head size or microcephaly with disorganized placement of cell types. Specific, localized malformations are termed focal cortical dysplasias (FCD).
View Article and Find Full Text PDFA Belgian physician-initiated trial investigating the LifeStream peripheral stent graft system for the treatment of complex TASC C and D iliac lesions.
J Cardiovasc Surg (Torino)
February 2025
Department of Vascular Surgery, AZ Sint Blasius, Dendermonde, Belgium.
Background: Due to the heterogeneity of literature findings, stent type selection for the endovascular treatment of complex aorto-iliac occlusive disease remains challenging. The BELSTREAM study, a physician-initiated, prospective, multicenter, single-arm study, aims to report the safety and efficacy of the balloon expandable LifeStream Peripheral Stent Graft System (BD, Tempe, Arizona, USA) for the treatment of complex TASC C and D aorto-iliac artery lesions.
Methods: Seventy patients and 133 lesions were included at six Belgian institutions.
Three-Dimensional CT for Preprocedural Planning of PCI for Ostial Right Coronary Artery Lesions: A Randomized Controlled Pilot Trial.
Circ Cardiovasc Interv
January 2025
Department of Cardiology, Ziekenhuis Oost-Limburg, Genk, Belgium (D.M.F.v.d.B., E.M.P., E.W., D.C., E.M., B.F., M.V., J.D., K.A.).
Background: Geographic stent-ostium mismatch is an important predictor of target lesion failure after percutaneous coronary intervention of an aorto-ostial right coronary artery lesion. Optimal visualization of the aorto-ostial plane is crucial for precise stent implantation at the level of the ostium. This study investigates whether preprocedural 3-dimensional computed tomography (3DCT), with determination of the optimal viewing angle, would allow for more precise stent implantation and reduce procedure time, contrast, and radiation dose.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!